{'fraction_non_alphanumeric': 0.03219315895372234, 'fraction_numerical': 0.02112676056338028, 'mean_word_length': 5.067073170731708, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Pronoran in the treatment of mental organic syndrome in the elderly].

Efficacy and tolerability of pronoran (piribedil) was investigated in an open clinical trial including 21 patients, aged 61-85 years, with initial cognitive disturbances of cerebral vascular genesis. Along with a clinical and somatic examination, the Clinical Global Impression (CGI) scale, the Mini Mental State Examination (MMSE) test, the Sandoz Clinical Assessment Geriatric (SCAG) scale and a scale for side-effects were used. Pronoran was prescribed in a dosage 50-100 mg/day during 3 months. Patients were examined at base line and on the treatment day 14, 42 and 90. A positive clinical effect on mild cognitive impairment was achieved after 1.5 months and maintained to the end of 3 month therapy. Pronoran improves ability to sustain attention, learning and memory, organization of thinking and executive mental function. It also has a mild antidepressive and antianxiety action, being safe for elderly patients.